A tricyclic antidepressant that has actions and uses similar to those of AMITRIPTYLINE, but has only weak antimuscarinic and sedative effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p257)
Tricyclic antidepressant similar to IMIPRAMINE, but with more antihistaminic and sedative properties.

Effects of iprindole on responses of single cortical and caudate neurones to monoamines and acetylcholine. (1/8)

1 The technique of microelectrophoresis was used to study the effects of iprindole on single neurones in the cerebral cortex and caudate nucleus of the rat. 2 Iprindole, when applied for a brief period, did not affect the firing rate of the vast majority of neurones tested. 3 Both potentiation and antagonism of neuronal responses to noradrenaline, dopamine, and 5-hydroxytryptamine could be observed after a brief application of iprindole. Potentiation and antagonism often occurred after the same application of iprindole, antagonism always preceding potentiation. 4 Responses to acetylcholine were affected by iprindole similarly: both potentiation and antagonism of the responses could be observed. 5 Responses to glutamate were not affected by iprindole. 6 It is concluded that the potentiation of responses to monoamines by iprindole cannot be explained on the basis of uptake blockade; this potentiation may be due to the blockade of masked receptors on the post-synaptic cell. 7. It is suggested that the common pharmacological action of the tricyclic antidepressants may be the ability to block both monoamine and acetylcholine receptors in the brain.  (+info)

Adverse pulmonary vascular effects of high dose tricyclic antidepressants: acute and chronic animal studies. (2/8)

Overdose of tricyclic antidepressants, which inhibit cellular serotonin (5-HT) uptake, sometimes causes acute respiratory syndrome-like symptoms. Their acute and chronic cardiopulmonary actions, which might be implicated, utilising both in vivo and ex vivo animal studies, were investigated in this study. Acute amitriptyline (AMI), iprindole and imipramine caused dose-dependent prolonged rises in pulmonary artery pressure and oedema in anaesthetised cats in vivo. Acute AMI, in isolated ex vivo blood-perfused rat lungs, also caused dose-dependent sustained vasoconstriction, which could be attenuated with either calcium channel inhibition or a nitric oxide donor. It was demonstrated that the pressor effects of AMI were not due to release of histamine, serotonin, noradrenaline, or the activities of cycloxygenase or lipoxygenase. After AMI, hypoxic pulmonary vasoconstriction and the pressor actions of 5-HT and noradrenaline were diminished, possibly due to uptake inhibition. Activities of the endothelial-based enzymes, nitric oxide synthase and endothelin-converting enzyme, were undiminished. Large acute doses of AMI caused oedema with rupture of capillaries and alveolar epithelium. Chronic iprindole raised pulmonary artery pressure and right ventricle (RV)/left ventricle (LV) + septal (S) weight. Chronic AMI led to attenuation of the pressor action of 5-HT, especially when associated with chronic hypoxic-induced pulmonary hypertension. RV/LV+S weight increased, attributable to LV decline. The acute and chronic effects observed might have relevance to clinical overdose, while the attenuation of acute effects offers possible therapeutic options.  (+info)

Effect of iprindole on the metabolism of trimipramine in the rat. (3/8)

Major metabolites of trimipramine in young male Sprague-Dawley rats are the result of alicyclic and aromatic ring oxidation. The four major urinary metabolites have been identified as 10-oxotrimipramine, 2-hydroxytrimipramine, 2-hydroxynortrimipramine, and 2-hydroxy-10-oxotrimipramine. When iprindole was administered to rats prior to trimipramine, the effect on trimipramine metabolism was profound. The formation of both 10-oxo metabolites was virtually completely inhibited; the production of 2-hydroxytrimipramine was significantly reduced while the metabolic formation of 2-hydroxynortrimipramine was increased. It is apparent from these preliminary results that metabolic alicyclic and aromatic hydroxylations are catalyzed by different cytochrome P450 isozymes and more than one P450 isozyme is involved in the aromatic ring oxidation of trimipramine and nortrimipramine.  (+info)

Interactions of iprindole with fenfluramine metabolism in rat brain and liver. (4/8)

An assay procedure utilizing electron-capture gas chromatography was developed for simultaneous analysis of fenfluramine and norfenfluramine. This method was applied to brain and liver samples from rats which had been injected with fenfluramine with or without pretreatment with iprindole. The tissues from rats treated with fenfluramine showed extensive formation of norfenfluramine, consistent with findings reported previously in the literature. Pretreatment with iprindole led to an increase in brain and liver levels of fenfluramine, and, unexpectedly, to a marked decrease in levels of norfenfluramine in these tissues. These findings suggest that iprindole blocks N-deethylation and that it may be a useful tool with which to study the effects of fenfluramine in the absence of norfenfluramine. The results also emphasize the importance of considering drug-drug interactions in future research on fenfluramine.  (+info)

Iprindole reverses the lamellar body deficiency of cultured L-2 cells. Possible implications in the reversal of surfactant deficiency. (5/8)

Type II alveolar epithelial cells in long-term culture typically lose the ability to synthesize surfactant together with a loss of the characteristic lamellar bodies in the cytoplasm of the cells. Iprindole, a cationic amphiphilic drug, induces lamellar body formation in cultured L-2 cells, a cell line derived from rat Type II cells, but devoid of lamellar bodies. With concentrations of 10(-7)-10(-5) M iprindole, which approximate therapeutic plasma concentrations in human subjects, the drug induced the formation of lamellar bodies within 8 hours of incubation. This effect on cell morphology was rapidly lost after withdrawal of the drug. At concentrations of iprindole which induced lamellar body formation, there was a significant increase in phospholipid content of the L-2 cells as well as an increase in disaturated phosphatidylcholine, an important constituent of surfactant. These studies suggest that the use of drugs such as iprindole may represent a novel approach in the augmentation of phospholipid (and possibly surfactant) content of Type II cells in the lung.  (+info)

On the pharmacology and biochemistry of the amine-uptake mechanism in human blood platelets. (6/8)

1. The uptake of 5-hydroxytryptamine (5-HT) by human blood platelets in vitro has been studied with the object of identifying the biochemical mechanisms involved.2. Drugs active in adrenergic systems are only moderate inhibitors of uptake, although prenylamine is as active as the less potent tricyclic anti-depressive drugs; phenoxybenzamine is almost inactive as a competitive inhibitor but is effective if pre-incubated with the platelets beforehand. This parallels its pharmacological pattern of action.3. Inhibitors of oxidative phosphorylation do not inhibit 5-HT uptake, but iodoacetate inhibits, if pre-incubated with the platelets; p-chloromercuribenzoate does also, when the platelets are suspended in synthetic medium, but not in plasma.4. Ouabain causes significant inhibition at 10(-7)M; by 10(-6)M it achieves its maximal effect, namely 40% inhibition; in K(+)-deficient medium, uptake falls to 30% of normal; the K(+)-dependent fraction of the uptake includes the ouabain-sensitive component. Mg(++) has no effect.5. A drug not possessing the imipramine structure, which has been tried in the treatment of depressive illness, 4-phenyl bicyclo (2,2,2) octan-1-amine, is a highly potent inhibitor of 5-HT uptake.  (+info)

Structure-activity relations for the inhibition of 5-hydroxytryptamine uptake by tricyclic antidepressants into synaptosomes from serotoninergic neurones in rat brain homogenates. (7/8)

1 The inhibitory effects of various analogues of imipramine on [(3)H]-5-hydroxytryptamine (5-HT) uptake into homogenates of rat hypothalamus were examined.2 For structures with a three carbon side chain the tertiary amine derivative was more potent than the compound with a secondary amine function.3 Potency was reduced by increasing or decreasing the length of the three carbon side chain by one carbon atom.4 Substitution of a methyl group in the alpha or beta position in the side chain reduced potency.5 Replacement of the dimethylene bridge in imipramine by a sulphur atom or substitution of a C=C double bond for the exocyclic N-C bond of imipramine both led to a fall in potency.6 3-Chlorimipramine was the most potent inhibitor of [(3)H]-5-hydroxytryptamine uptake of the compounds tested.  (+info)

Potentiation of the action of adenosine on cerebral cortical neurones by the tricyclic antidepressants. (8/8)

The effects of four tricyclic antidepressants, nortriptyline, iprindole, chlorimipramine and desipramine on adenosine-evoked depressions of the firings of rat cerebral cortical neurones has been studied. When applied iontophoretically, all four substances enhanced the depressant actions of iontophoretically applied adenosine but did not affect the depressant actions of the uptake-resistant analogue, adenosine 5'-N-ethylcarboxamide (NECA). Nortriptyline and iprindole administered intravenously (1 mg kg-1) enhanced the depressant actions of iontophoretically applied adenosine. When applied by larger iontophoretic currents, all four antidepressants inhibited the firing of cerebral cortical neurones. Chlorimipramine- and desimipramine-elicited depressions were antagonized by intravenously administered caffeine, an adenosine antagonist. Earlier studies showed the tricyclic antidepressants inhibit the uptake of adenosine by rat brain cerebral cortical synaptosomes. The present results demonstrate that four antidepressants are able to potentiate the action of adenosine and that this occurs when these compounds are given in behaviourally meaningful doses. The specificity of the potentiation is demonstrated by the failure of these compounds to potentiate the depressant actions of an uptake-resistant analogue of adenosine, NECA. Antagonism of the inhibitory effects of the antidepressants on neuronal firings by caffeine, indicates that these compounds can enhance the extracellular levels of endogenously released adenosine sufficiently to depress cell firing.  (+info)

Iprindole is a tricyclic antidepressant that was used for the treatment of depression. It works by increasing the levels of neurotransmitters (chemical messengers) in the brain, such as serotonin and noradrenaline, which help to regulate mood and emotion.

Iprindole has been discontinued in many countries due to its limited efficacy and unfavorable side effect profile compared to other antidepressants. Some of the common side effects associated with iprindole include dry mouth, blurred vision, constipation, dizziness, drowsiness, and weight gain.

It is important to note that iprindole should only be taken under the supervision of a healthcare provider, as it can interact with other medications and have serious side effects if not used properly.

Trimipramine is a type of antidepressant known as a tricyclic, which is used primarily to treat major depressive disorder. It works by increasing the levels of certain neurotransmitters (chemical messengers) in the brain, such as serotonin and norepinephrine, which help to regulate mood.

Trimipramine also has sedative properties and is sometimes used off-label for the treatment of insomnia or anxiety. It is available in immediate-release and extended-release forms, and is typically taken orally.

As with all medications, trimipramine can have side effects, which may include dry mouth, blurred vision, constipation, dizziness, drowsiness, and weight gain. In rare cases, it may cause more serious side effects such as heart rhythm abnormalities, seizures, or increased suicidal thoughts or behaviors in some individuals, particularly in children and adolescents.

It is important to take trimipramine exactly as prescribed by a healthcare provider, and to discuss any potential risks or benefits with them before starting treatment.

  • The binding affinities of iprindole for various biological targets are presented in the table to the right. (wikipedia.org)
  • Iprindole has been associated with jaundice and hepatotoxicity and should not be taken by alcoholics or people with pre-existing liver disease. (wikipedia.org)
  • Jaundice due to iprindole. (forexsignal300.com)
  • Anticholinergic side effects such as dry mouth and constipation are either greatly reduced in comparison to imipramine and most other TCAs or fully lacking with iprindole. (wikipedia.org)
  • For instance, between 1974 and 1985, only two deaths associated with iprindole were recorded in the United Kingdom, whereas 278 were reported for imipramine, although imipramine is used far more often than iprindole. (wikipedia.org)
  • The mean terminal half-life of iprindole was 52.5 hours, which is notably much longer than that of other TCAs like amitriptyline and imipramine. (wikipedia.org)
  • On account of these interactions, caution should be used when combining iprindole with other drugs. (wikipedia.org)

No images available that match "iprindole"